Determinants of clinical outcome and survival in acromegaly, Clinical Endocrinology, vol.153, issue.4, pp.95-102, 1994. ,
DOI : 10.2307/2281868
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA), Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry, pp.439-446, 2004. ,
DOI : 10.1530/eje.0.1510439
Acromegaly, Endocrinology and Metabolism Clinics of North America, vol.37, issue.1, p.101, 2008. ,
DOI : 10.1016/j.ecl.2007.10.002
Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients, Journal of Neurosurgery, vol.68, issue.6, pp.854-867, 1988. ,
DOI : 10.3171/jns.1988.68.6.0854
« Physiologie de l'axe somatotrope », in Traité d'endocrinologie, Médecine-Sciences, Flammarion, 2007. ,
« Physiologie de la sécrétion de l'hormone de croissance, Med. Thérapeutique Endocrinol, vol.4, pp.4-14, 2002. ,
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.3, 2013. ,
DOI : 10.1210/jc.2004-1093
«New somatostatin analogs : therapeutical perspectives, Métab. Hormon. Diabètes et Nut, vol.10, pp.3-4, 2006. ,
Somatostatin receptor subtype expression in human tumors, Annals of Oncology, vol.12, issue.suppl 2, pp.31-36, 2000. ,
DOI : 10.1093/annonc/12.suppl_2.S31
Clinical Manifestations and Diagnosis of Acromegaly, International Journal of Endocrinology, vol.47, issue.2, 2012. ,
DOI : 10.1210/jc.2007-1191
Acromegaly, New England Journal of Medicine, vol.355, issue.24, pp.2558-257391, 2006. ,
DOI : 10.1056/NEJMra062453
URL : https://hal.archives-ouvertes.fr/hal-00017712
Growth hormone and the heart, Growth hormone and the heart, pp.137-154, 2001. ,
DOI : 10.1210/en.137.5.1798
Epithelial Sodium Channel Is a Key Mediator of Growth Hormone-Induced Sodium Retention in Acromegaly, Endocrinology, vol.149, issue.7, pp.3294-3305, 2008. ,
DOI : 10.1210/en.2008-0143
URL : https://hal.archives-ouvertes.fr/inserm-00266634
Increased Prevalence of Regurgitant Valvular Heart Disease in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.1, pp.71-75, 2004. ,
DOI : 10.1210/jc.2003-030849
Acromegalic Cardiomyopathy: A Review of the Literature, Pituitary, vol.6, issue.4, pp.203-207, 2003. ,
DOI : 10.1023/B:PITU.0000023427.31609.a2
Endocrine Aspects of Obstructive Sleep Apnea, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.2, pp.483-495, 2010. ,
DOI : 10.1210/jc.2009-1912
Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease, European Journal of Endocrinology, vol.159, issue.5, pp.533-540, 2008. ,
DOI : 10.1530/EJE-08-0442
Craniofacial abnormalities and their relevance for sleep apnoea syndrome aetiopathogenesis in acromegaly, European Journal of Endocrinology, vol.144, issue.5, pp.491-497, 2001. ,
DOI : 10.1530/eje.0.1440491
« Savoir reconnaître les signes de l'acromégalie -Apnées du sommeil et acromégalie ,
CLINICAL PERSPECTIVE: Acromegaly and Cancer: Not a Problem?, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.7, pp.2929-2934, 2001. ,
DOI : 10.1210/jcem.86.7.7635
Mortality and Cancer Incidence in Acromegaly, The Journal of Urology, vol.83, issue.8, pp.2730-2734, 1998. ,
DOI : 10.1097/00005392-199904000-00103
CLINICAL PERSPECTIVE: Acromegaly and Cancer: A Problem, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.7, pp.2935-294191, 2001. ,
DOI : 10.1210/jcem.86.7.7634
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly, European Journal of Endocrinology, vol.159, issue.2, pp.89-95, 2008. ,
DOI : 10.1530/EJE-08-0267
Does treatment of acromegaly affect life expectancy?, Metabolism, vol.44, pp.1-5, 1995. ,
DOI : 10.1016/0026-0495(95)90303-8
« Primary medical therapy for acromegaly : an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor I, and tumor size, J. Clin. Endocrinol. Metab, vol.87, issue.10, pp.4554-4563, 2002. ,
Excess Mortality in Acromegaly, Excess mortality in acromegaly, pp.166-172, 2007. ,
DOI : 10.1159/000110617
Factors Influencing Mortality in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.2, pp.667-674, 2004. ,
DOI : 10.1210/jc.2003-031199
Mortality in Acromegaly: A Metaanalysis, Mortality in acromegaly: a metaanalysis, pp.61-67, 2008. ,
DOI : 10.1210/jc.2007-1191
« The role of insulinlike growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery, pp.411-415, 2010. ,
« Recommandations pour l'harmonisation des techniques de dosage sérique d'hormone de croissance, Ann. Biol. Clin, vol.62, pp.155-163, 2004. ,
Surgical Management of GH-Secreting Pituitary Adenomas: An Outcome Study Using Modern Remission Criteria, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.9, pp.4072-4077, 2001. ,
DOI : 10.1210/jcem.86.9.7819
A Consensus on Criteria for Cure of Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.7, pp.3141-3148, 2010. ,
DOI : 10.1210/jc.2009-2670
« A nationwide survey of mortality in acromegaly, J. Clin. Endocrinol. Metab, vol.90, issue.7, pp.4081-4086, 2005. ,
Roelfsema, « Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor i measurements, p.91 ,
Consensus fran??ais sur la prise en charge de l???acrom??galie, Consensus français sur la prise en charge de l'acromégalie, pp.9-22, 2009. ,
DOI : 10.1016/j.ando.2008.12.010
Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience, Clinical Endocrinology, vol.39, issue.5, pp.561-567, 1999. ,
DOI : 10.1046/j.1365-2265.1996.8370847.x
Anaesthetic complications of acromegaly, Anaesthetic complications of acromegaly. », pp.179-182, 2000. ,
DOI : 10.1093/oxfordjournals.bja.a013400
Direct Postoperative and Follow-Up Results of Transsphenoidal Surgery in 19 Acromegalic Patients Pretreated with Octreotide Compared to Those in Untreated Matched Controls, The Journal of Clinical Endocrinology & Metabolism, vol.84, issue.10, pp.3551-3555, 1999. ,
DOI : 10.1210/jcem.84.10.6027
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure', European Journal of Endocrinology, vol.152, issue.3, pp.379-387, 2005. ,
DOI : 10.1530/eje.1.01863
Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.9, pp.2732-2740, 2011. ,
DOI : 10.1210/jc.2011-0554
Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly, European Journal of Endocrinology, vol.150, issue.6, pp.763-771, 2004. ,
DOI : 10.1530/eje.0.1500763
Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly, Journal of Neurosurgery, vol.89, issue.3, pp.353-358, 1998. ,
DOI : 10.3171/jns.1998.89.3.0353
Transsphenoidal Microsurgery for Growth Hormone-Secreting Pituitary Adenomas: Initial Outcome and Long-Term Results, The Journal of Clinical Endocrinology & Metabolism, vol.83, issue.10, pp.3411-3418, 1998. ,
DOI : 10.1210/jcem.83.10.5111
« Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly, J. Clin. Endocrinol. Metab, vol.80, issue.11, pp.3267-3272, 1995. ,
Sandostatin?? LAR?? (microencapsulated octreotide acetate) in acromegaly: Pharmacokinetic and pharmacodynamic relationships, Metabolism, vol.45, pp.27-30, 1996. ,
DOI : 10.1016/S0026-0495(96)90075-X
Primary medical therapy for acromegaly, Clinical Endocrinology, vol.39, issue.4, pp.387-399, 2003. ,
DOI : 10.1046/j.1365-2265.1996.8080817.x
« Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly, Pituitary, vol.3, issue.3, pp.193-197, 2000. ,
DOI : 10.1023/A:1011416112730
Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study., The Journal of Clinical Endocrinology & Metabolism, vol.80, issue.9, pp.2768-2775, 1995. ,
DOI : 10.1210/jcem.80.9.7673422
A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.8, pp.2957-2968, 2008. ,
DOI : 10.1210/jc.2008-0027
Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in Acromegaly, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.6, pp.2779-2786, 2001. ,
DOI : 10.1210/jc.86.6.2779
Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure, Clinical Endocrinology, vol.87, issue.6, pp.736-743, 2011. ,
DOI : 10.1111/j.1365-2265.2011.03982.x
Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre, European Journal of Endocrinology, vol.145, issue.2, pp.137-145, 2001. ,
DOI : 10.1530/eje.0.1450137
« Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly, Clin. Endocrinol, vol.56, pp.65-71, 2002. ,
Somatostatin Analogs in Acromegaly, Somatostatin analog in acromegaly, pp.3013-3018, 2002. ,
DOI : 10.1210/jcem.87.7.8665
Sandostatin LAR in Acromegalic Patients: Long Term Treatment, The Journal of Clinical Endocrinology & Metabolism, vol.82, issue.1, pp.23-28, 1997. ,
DOI : 10.1210/jcem.82.1.3572
Efficacit?? et tol??rance du pegvisomant en pratique r??elle??: analyse interm??diaire de l?????tude ACROstudy France, Annales d'Endocrinologie, vol.75, issue.5-6, pp.5-6, 2014. ,
DOI : 10.1016/j.ando.2014.07.168
Radiotherapy and radiosurgery in acromegaly, Pituitary, vol.4, issue.Suppl 3, pp.3-10, 2009. ,
DOI : 10.1007/s11102-007-0078-y
Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: A prospective study of 110 patients, International Journal of Radiation Oncology*Biology*Physics, vol.62, issue.2, pp.333-341, 2005. ,
DOI : 10.1016/j.ijrobp.2004.09.058
Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly, The Journal of Clinical Endocrinology & Metabolism, vol.82, issue.10, pp.3308-3314, 1997. ,
DOI : 10.1210/jcem.82.10.4283
Preoperative Treatment of Acromegaly with Long-Acting Somatostatin Analog SMS 201-995: Shrinkage of Invasive Pituitary Macroadenomas and Improved Surgical Remission Rate*, The Journal of Clinical Endocrinology & Metabolism, vol.67, issue.5, pp.1040-1048, 1988. ,
DOI : 10.1210/jcem-67-5-1040
« Octreotide as primary therapy for acromegaly, J. Clin. Endocrinol. Metab, vol.83, issue.88, pp.3034-304091, 1998. ,
Does Octreotide Treatment Improve the Surgical Results of Macro-Adenomas in Acromegaly? A Randomized Study, Acta Neurochirurgica, vol.141, issue.4, pp.399-405, 1999. ,
DOI : 10.1007/s007010050316
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009. ,
DOI : 10.1016/j.ejca.2008.10.026
Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis, Brain and Development, vol.37, issue.2, pp.181-190, 2015. ,
DOI : 10.1016/j.braindev.2014.04.009
surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study, Clinical Endocrinology, vol.47, issue.5, pp.757-768, 2009. ,
DOI : 10.1111/j.1365-2265.2008.03441.x
Preoperative Octreotide Treatment in Newly Diagnosed Acromegalic Patients with Macroadenomas Increases Cure Short-Term Postoperative Rates: A Prospective, Randomized Trial, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.8, pp.2984-2990, 2008. ,
DOI : 10.1210/jc.2008-0315
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study, Endocrine Journal, vol.57, issue.12, pp.12-1035, 2010. ,
DOI : 10.1507/endocrj.K10E-203
Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial, European Journal of Endocrinology, vol.162, issue.4, pp.661-666, 2010. ,
DOI : 10.1530/EJE-09-0908
Preoperative Lanreotide Treatment Improves Outcome in Patients with Acromegaly Resulting from Invasive Pituitary Macroadenoma, Journal of International Medical Research, vol.93, issue.2, pp.517-524, 2012. ,
DOI : 10.1177/147323001204000213
Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system, Pituitary, vol.64, issue.4, pp.500-508, 2015. ,
DOI : 10.1007/s11102-014-0602-9
Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial, European Journal of Endocrinology, vol.171, issue.2, pp.229-235, 2014. ,
DOI : 10.1530/EJE-14-0249
« Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome : a systematic review and meta-analysis, Plosone, vol.8, issue.4, 2013. ,
(long-acting repeatable octreotide) in the primary therapy of patients with acromegaly, Clinical Endocrinology, vol.29, issue.6, pp.859-868, 2007. ,
DOI : 10.1210/jc.85.2.781
Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.4, pp.1397-1403, 2006. ,
DOI : 10.1210/jc.2005-2347
Long-term (up to 18??years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa, Clinical Endocrinology, vol.87, issue.Suppl. 1, pp.282-289 ,
DOI : 10.1111/j.1365-2265.2007.02878.x
Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.10, pp.3746-3756, 2009. ,
DOI : 10.1210/jc.2009-0941
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY?, Endocrine Practice, vol.21, issue.6, pp.668-67391, 2015. ,
DOI : 10.4158/EP14575.DSCR